We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
This legal manoeuvre is setting a new precedent for corporations to evade accountability in America
US drugmaker seeks more tie-ups after existing collaboration yields new cancer treatment
Ruling opens a fresh chapter for resolving US tort cases
Fight moves to Congress after judge allows J&J to use scheme to help it settle billions in legal claims
Decision allows group to use the manoeuvre to manage tens of thousands of claims that its baby talc caused cancer
Lawyer who drafted statute says companies should not deploy it to ‘skirt’ their obligations
Asset managers call for pharma executive pay to be linked to equitable distribution of jabs
Two doses cut likelihood by up to 85%, according to real-world South African research
Country tackles one of the first waves of infections caused by Omicron variant
Drugmakers are stress-testing existing jabs while preparing new formulas
Plan to spin off consumer division has failed to thrill investors
Advisers benefit from multinationals’ current wave of spin-offs
A successful split of the consumer and pharma divisions would, on paper, unlock value
World’s largest healthcare group follows trend to slim down with plans to focus on pharmaceuticals
World’s largest healthcare company uses unusual legal manoeuvre to contain talc-based baby powder liabilities
Abusive deployment of Chapter 11 protection can erode consumer confidence
People at high risk of catching coronavirus can now receive any of three vaccines authorised by US health agency
Healthcare group created a subsidiary to manage allegations then placed it into bankruptcy
Lawyer for plaintiffs claims drugmaker is trying to limit payouts to cancer sufferers
Panel recommends third jabs for vulnerable people in step towards expanding US rollout of extra doses
Albert Bourla believes it is ‘feasible’ to inoculate at least 10% of people in every country
Data come amid debate over whether additional jabs are needed to increase protection
Company veteran Joaquin Duato, Gorsky’s longtime protégé, takes up the reins
Incoming chief executive has overseen health products and drugmaker’s response to Covid-19
International Edition
